Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MK-571 sodium (L-660711 sodium salt) is a selective, orally active antagonist of the CysLT1 receptor. MK-571 sodium is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK-571 sodium can inhibit the synthesis of K-4′-O-GlcA (19.7 μM). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK-571 sodium significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4′-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 47.00 | |
10 mg | In stock | $ 77.00 | |
25 mg | In stock | $ 177.00 | |
50 mg | In stock | $ 317.00 | |
100 mg | In stock | $ 473.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 63.00 |
Description | MK-571 sodium (L-660711 sodium salt) is a selective, orally active antagonist of the CysLT1 receptor. MK-571 sodium is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK-571 sodium can inhibit the synthesis of K-4′-O-GlcA (19.7 μM). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK-571 sodium significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4′-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation. |
Targets&IC50 | LTD 4:0.22 nM (Ki, In guinea pig lung), LTD 4:2.1 nM (Ki, In human lung) |
Cell Research | Cells were seeded onto 96 well plates at a concentration of 1×103 cells per well and incubated for 72 h at 37?C and 5% CO2 to allow MRP1 messenger RNA suppression to occur. Cells were then treated with either control media or one of three chemotherapy drugs temozolomide (150 µM), vincristine (100 nM), or etoposide (2 µM). Cells were then returned to the incubator for a further 72 h; after which time, Metylthiazol Tetrazolium (MTT) powder in PBS (50µl of 5 mg/ml) was added to each well. Cells were then incubated for a further 4 h after which all solution was removed and dimethyl sulfoxide (DMSO) was added. After 10 min incubation time at 37?C, absorbance was recorded at 570 nm wavelength and data was recorded and analyzed. Small molecule inhibitors MK571 (25 µM) and Reversan (15µM) were added 7 h prior to carrying out further drug treatment (temozolomide, vincristine or etoposide) or assay assessment (media change for proliferation and 2D-migration assays) (Only for Reference) |
Synonyms | L-660711 (sodium salt), L-660711 sodium salt, Verlukast sodium, L-660711, MK571, MK-571 sodium salt, Propanoic acid |
Molecular Weight | 537.07 |
Formula | C26H27ClN2O3S2·Na |
CAS No. | 115103-85-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (173.2 mM)
Ethanol: 16 mg/mL (29.8 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MK-571 sodium 115103-85-0 GPCR/G Protein Immunology/Inflammation Leukotriene Receptor LTR L 660711 MRP4 MK-571 Lysophospholipid Receptor human mast cells LAD2 MK 571 sodium MRP1 sphingosine kinase L-660711 (sodium salt) L-660711 sodium ABCC1 L-660711 sodium salt LPL Receptor bronchoconstriction Sphingolipids Inhibitor L660711 Verlukast sodium ATP-binding cassette pulmonary hypertension L-660711 inhibit MK571 MK-571 sodium salt dyspnea MK 571 MK571 sodium Propanoic acid RBL-2H3 cells inhibitor